Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — FY2025 Earnings Presentation
24 slides from Collegium Pharmaceutical's earnings presentation, Feb 26, 2026
Slide 1: Q4 and FY2025 Earnings Report
Q4 and FY2025 Earnings Report February 26, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 3: Business Update
Business Update Vikram Karnani President & Chief Executive Officer
Slide 4: Building a Leading, Diversified Biopharmaceutical Company
4 Building a Leading, Diversified Biopharmaceutical Company 1. This financial data was provided by Collegium in its Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. Healthier people. Str
Slide 5: Recent Business Highlights
Recent Business Highlights1 1. Unless otherwise noted, this financial data was provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2.
Slide 6: Strategic Priorities to Drive Value Creation
Drive further growth for Jornay PM 6 Strategic Priorities to Drive Value Creation Grows revenue Extends longevity Increases profitability Generates robust cash flows Diversifies portfolio Strengthens balance sheet VALUE CREATION 2026 Strategic Priorities Maximize the durability of the Pa
Slide 7: Collegium's Vision for the Next Phase of Growth
Collegium’s Vision for the Next Phase of Growth 7 Time O pp or tu ni ty FUTURE FURTHER EXPANSION Product diversification and capital deployment NEUROPSYCHIATRY and PEDIATRICS PAIN PORTFOLIO FUTURE
Slide 8: Commercial Update
Commercial Update Scott Dreyer Executive Vice President & Chief Commercial Officer
Slide 9: Product Differentiation and Strong Brand Fundamentals Drive Utilization
Product Differentiation and Strong Brand Fundamentals Drive Utilization1 91. ATU (Awareness, Trial, & Usage) Market Research Study, completed Q2 2025. Strong Intent to Increase PrescribingJornay PM Considered Highly Differentiated #1 highest rated branded ADHD medicine in terms of product differenti
Slide 10: Fastest Growing Stimulant for Treatment of ADHD
Q4'24 Q4'25Q4'24 Q4'25 Fastest Growing Stimulant for Treatment of ADHD 10 STRONG AND GROWING PRESCRIBER BASE2 GROWTH IN QUARTERLY PRESCRIPTIONS1 MARKET SHARE IN BRANDED LONG-ACTING METHYLPHENIDATE MARKET1 Q4'24 Q4'25 +16% +21% GROWTH IN AVERAGE WEEKLY PRESCRIPTIONS DURING “BACK-TO- SCHOOL” SEASON1 J
Slide 11: Investing in Jornay PM to Drive Additional Momentum
Investing in Jornay PM to Drive Additional Momentum 11 1. Increase awareness and adoption with expanded set of prescribers 2. Raise caregiver and patient awareness to drive HCP request 3. Increase depth of prescribing with targeted physicians 4. Maintain broad patient access $149M $190 – 200M 2025 2
Slide 12: Well Positioned to Maximize Durability of Responsible Pain Management Portfolio
12 Well Positioned to Maximize Durability of Responsible Pain Management Portfolio 1. This financial data was provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. ATU (Awareness, Trial, & Usage) Market Research Study, field
Slide 13: Financial Highlights
Financial Highlights Colleen Tupper Executive Vice President & Chief Financial Officer
Slide 14: Q4 and FY2025 Financial Highlights
Q4 and FY2025 Financial Highlights1 14 1. This financial data was provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. $631M $781M
Slide 15: 2026 Financial Guidance
2026 Guidance Range2 YoY Change3 Product Revenues, Net $805 – 825M +4% Jornay PM Revenue, Net $190 – 200M +31% Adjusted EBITDA1 $455 – 475M +1% 2026 Financial Guidance 15 1. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. 2. This financial data was provide
Slide 16: Disciplined Capital Deployment
Disciplined Capital Deployment 16 1. Adjusted EBITDA is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the
Slide 17: Disciplined Business Development Approach
Disciplined Business Development Approach TARGET THERAPEUTIC AREAS • Neuropsychiatry and pediatrics • Other specialty conditions (case-by-case) • Rare diseases (case-by-case) Guiding Framework for Near-term BD Efforts ADDITIONAL FEATURES While maintaining robust cash generation and financial strengt
Slide 18: Closing Remarks
Closing Remarks Vikram Karnani President & Chief Executive Officer
Slide 19: Creating Value for Shareholders
Creating Value for Shareholders 19 19 2026 STRATEGIC PRIORITIES VALUE CREATION 1. Drive significant growth for Jornay PM 2. Maximize the durability of the Pain Portfolio 3. Strategically deploy capital • Business Development • Debt repayment • Share repurchases Grow Revenues Extend longevity Increas
Slide 20: Healthier people. Stronger communities.
20 Healthier people. Stronger communities. Building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
Slide 21: Non-GAAP Reconciliations
Non-GAAP Reconciliations <@ Collegi v once
Slide 22: Reconciliation of GAAP Net Income to Adjusted EBITDA
Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands, unaudited) 22 GAAP net income $ 16,963 $ 12,536 $ 62,870 $ 69,190 Adjustments: Interest expense 19,292 22,654 82,312 73,974 Interest income (3,565) (1,812) (11,289) (13,976) Loss on extinguishment of debt 15,994 — 15,994 11,329 Prov
Slide 23: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands, unaudited) 23 GAAP operating expenses $ 67,621 $ 60,177 $ 283,621 $ 207,449 Adjustments: Stock-based compensation 9,753 7,596 41,906 32,400 Executive transition expense — — 1,397 3,051 Acquisition related expense
Slide 24: Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted EPS
Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts, unaudited) 24 1. The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax e
Collegium Pharmaceutical — FY2025 Earnings Presentation on 6ix